ES2530972T3 - Métodos de tratamiento de trastornos - Google Patents

Métodos de tratamiento de trastornos Download PDF

Info

Publication number
ES2530972T3
ES2530972T3 ES04788727T ES04788727T ES2530972T3 ES 2530972 T3 ES2530972 T3 ES 2530972T3 ES 04788727 T ES04788727 T ES 04788727T ES 04788727 T ES04788727 T ES 04788727T ES 2530972 T3 ES2530972 T3 ES 2530972T3
Authority
ES
Spain
Prior art keywords
treatment
disorders
methods
formula
aminocarbonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04788727T
Other languages
English (en)
Inventor
Andrew Napper
Peter Distefano
Jeffrey Hixon
Thomas Mcdonagh
Jonathan Solomon
L Julie Huber
Rory Curtis
Russell J Thomas
Jean-Francois Pons
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elixir Pharmaceuticals Inc
Original Assignee
Elixir Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elixir Pharmaceuticals Inc filed Critical Elixir Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2530972T3 publication Critical patent/ES2530972T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la siguiente fórmula (XI):**Fórmula** en la que R6 es halo o alquilo y R5 es aminocarbonilo para su uso en la prevención o el tratamiento de un trastorno neurodegenerativo.
ES04788727T 2003-09-12 2004-09-13 Métodos de tratamiento de trastornos Expired - Lifetime ES2530972T3 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US50281103P 2003-09-12 2003-09-12
US53144303P 2003-12-19 2003-12-19
US56050904P 2004-04-07 2004-04-07
PCT/US2004/029942 WO2005026112A2 (en) 2003-09-12 2004-09-13 Methods of treating a disorder

Publications (1)

Publication Number Publication Date
ES2530972T3 true ES2530972T3 (es) 2015-03-09

Family

ID=34317479

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04788727T Expired - Lifetime ES2530972T3 (es) 2003-09-12 2004-09-13 Métodos de tratamiento de trastornos

Country Status (6)

Country Link
US (1) US20050209300A1 (es)
EP (1) EP1677794B1 (es)
JP (1) JP4908215B2 (es)
CA (1) CA2538759C (es)
ES (1) ES2530972T3 (es)
WO (1) WO2005026112A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7977049B2 (en) 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
WO2005004814A2 (en) * 2003-07-02 2005-01-20 Elixir Pharmaceuticals, Inc. Sirt1 and genetic disorders
US20060074124A1 (en) * 2003-09-12 2006-04-06 Andrew Napper Methods of treating a disorder
US7314886B2 (en) * 2003-10-02 2008-01-01 Cephalon, Inc. Tetrahydropyrano-indole derivatives
CA2550091A1 (en) * 2003-12-19 2005-07-07 Elixir Pharmaceuticals, Inc. Methods of treating a disorder
US20050171027A1 (en) 2003-12-29 2005-08-04 President And Fellows Of Harvard College Compositions for treating or preventing obesity and insulin resistance disorders
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
CA2588389A1 (en) 2004-11-23 2006-06-22 Ptc Therapeutics, Inc. Substituted phenols as active agents inhibiting vegf production
GB2422828A (en) * 2005-02-03 2006-08-09 Hunter Fleming Ltd Tricyclic cytoprotective compounds comprising an indole residue
EP1853590A1 (en) 2005-03-03 2007-11-14 Sirtris Pharmaceuticals, Inc. Fused heterocyclic compounds and their use as sirtuin modulators
WO2006138418A2 (en) 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
US20090022694A1 (en) * 2005-10-18 2009-01-22 Distefano Peter Sirt1 inhibition
EP1891949A1 (en) * 2006-08-14 2008-02-27 Santhera Pharmaceuticals (Schweiz) AG Use of tricyclic indole derivatives for the treatment of muscular atrophy
WO2008019825A1 (en) * 2006-08-14 2008-02-21 Santhera Pharmaceuticals (Schweiz) Ag Use of tricyclic indole derivatives for the treatment of muscular diseases
EP2142669A4 (en) * 2007-04-12 2012-01-04 Harvard College SIRTUINE-BASED METHODS AND COMPOSITIONS FOR TREATING B-CATENIN RELATED DISORDERS
WO2009099643A1 (en) * 2008-02-07 2009-08-13 The J. David Gladstone Institutes Use of sirt1 activators or inhibitors to modulate an immune response
EP2367563A4 (en) 2008-12-08 2012-12-19 Univ Northwestern METHOD FOR MODULATING HSF-1
WO2012142256A2 (en) * 2011-04-12 2012-10-18 The Regents Of The University Of California Modulators of mitochondrial protein import
AR088377A1 (es) * 2011-10-20 2014-05-28 Siena Biotech Spa Proceso para la preparacion de 6-cloro-2,3,4,9-tetrahidro-1h-carbazol-1-carboxamida y compuestos intermedios de esta
CN107072205B (zh) * 2014-09-10 2022-07-15 Epizyme股份有限公司 Smyd抑制剂
EP3230279A1 (en) 2014-12-10 2017-10-18 Massachusetts Institute of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
BR112018016133A2 (pt) 2016-02-16 2019-01-02 Massachusetts Inst Technology aglutinantes de max como moduladores de myc e usos dos mesmos

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3769298A (en) * 1971-04-02 1973-10-30 Pfizer Substituted aminomethylcarbazoles
BE793493A (fr) * 1971-12-30 1973-06-29 Hoffmann La Roche Composes tricycliques
DE2226703A1 (de) * 1972-05-25 1973-12-13 Schering Ag Neue tetrahydrocarbazolderivate und verfahren zu ihrer herstellung
US4009181A (en) * 1973-01-22 1977-02-22 Hoffmann-La Roche Inc. Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
BG25793A3 (en) * 1973-07-18 1978-12-12 Schering Aktiengesellschaft A method of obtaining carbasole derivatives
DE2431292A1 (de) * 1974-06-27 1976-01-15 Schering Ag Neue carbazol-derivate
CZ24197A3 (en) * 1994-07-27 1997-08-13 Sankyo Co Heterocyclic compounds, usable as allosteric efectors in muscarine receptors
US6045398A (en) * 1995-07-10 2000-04-04 International Business Machines Corporation Battery accepting unit and battery pack
US5830911A (en) * 1996-08-14 1998-11-03 American Home Products Corporation Pyranoindole and tetrahydrocarbazole inhibitors of COX-2
AU2002315166A1 (en) * 2001-06-15 2003-01-02 The Trustees Of Columbia University In The City Of New York Sir2alpha-based therapeutic and prophylactic methods
MXPA04005768A (es) * 2001-12-14 2004-09-10 Zentaris Gmbh Derivados de tetrahidrocarbazol como ligandos para receptores acoplados a proteina g (gpcr).
WO2003062392A2 (en) * 2002-01-18 2003-07-31 Ceretek Llc Methods of treating conditions associated with an edg receptor

Also Published As

Publication number Publication date
CA2538759A1 (en) 2005-03-24
JP4908215B2 (ja) 2012-04-04
JP2007505148A (ja) 2007-03-08
EP1677794B1 (en) 2014-12-03
US20050209300A1 (en) 2005-09-22
WO2005026112A2 (en) 2005-03-24
CA2538759C (en) 2015-11-03
WO2005026112A3 (en) 2005-11-24
EP1677794A2 (en) 2006-07-12
EP1677794A4 (en) 2010-05-19

Similar Documents

Publication Publication Date Title
ES2530972T3 (es) Métodos de tratamiento de trastornos
AR082825A2 (es) Inhibidores heterociclicos nitrogenados de mek, composiciones farmaceuticas que los contienen, metodos para prepararlos y uso de los mismos para el tratamiento de trastornos hiperproliferativos o inflamatorios
ECSP077401A (es) Medicamentos que contienen compuestos de carbonilo y su uso
UA88166C2 (ru) Применение пептидных соединений для лечения эссенцильного дрожания и других синдромов дрожания
CY1116754T1 (el) Παραγωγα νιτροκατεχολης ως αναστολεις της comt
CY1108738T1 (el) Θεραπευτικοι παραγοντες χρησιμοι για την αγωγη του πονου
BRPI0413582B8 (pt) compostos, composições e métodos para inibir a atividade de proteasome
DE60319364D1 (de) Substituierte pyrroline als kinase inhibitoren
EA200702358A1 (ru) Комбинация ингибитора pde4 и производного тетрагидробиоптерина
CR9272A (es) Amino-imidazolonas para la inhibicion de b-secretasa
UY28074A1 (es) Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiperproliferativos
DE60327306D1 (de) Modifizierter russ
BR0213981A (pt) Fotoiniciadores difuncionais
CL2007002384A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis.
TW200716183A (en) Parakeratosis inhibitor, pore-contracting agent and external composition for skin
CL2007002380A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento terapeutico y/o profilactico de la queratosis actinica.
TW200630367A (en) Substituted adenines and the uses thereof
TNSN06138A1 (fr) Inhibitors of the mutant form of kit
RS51069B (sr) Upotreba oksikodona za tretiranje visceralnog bola
CR8177A (es) Compuestos de 3- arilpiridina arilcondensados y su empleo para combatir hongos nocivos
EA200801351A1 (ru) Фунгицидные смеси, которые содержат боскалид и пириметанил
CL2007002387A1 (es) Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de artritis y dolor.
HN2002000110A (es) Uso de (z) - 2 - ciano - 3 - hidroxi - butil - 2 - acido enoico (4' - trifluorometil fenilo) - amida para el tratamiento de la esclerosis multiple.
UY29774A1 (es) Inhibidor de atm
BR0307595A (pt) Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico